Back to results
US 9,234,174 B2Granted
Tolerogenic dendritic cells, method for their production and uses therof
AssigneesOspedale San Raffaele S.R.L., Fondazione Telethon
InventorsSilvia Adriana Gregori, Maria Grazia Roncarolo, Rosa Bacchetta
Life of this patent
Estimating the term…
Abstract
The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.
Claims15
An in vitro method for generating a population of human tolerogenic dendritic cells (Tr-DC) comprising the steps of:
- a) collecting peripheral blood mononuclear cells (PBMCs) from a subject;
- b) isolating adherent cells from collected PBMCs;
- and
- c) exposing said isolated adherent cells at the start of culture on day 0 to an effective amount of GM-CSF, IL-4 and IL-10 to generate human Tr-DC,
- wherein the generated human Tr-DC have a mature myeloid phenotype and have a marker phenotype comprising:
- CD14+, CD11c+, CD11 b+, CD83+, CD80+, CD86+, HLA-DR+, CD71+ and CD1a−;
- wherein at least about 92% of the generated human Tr-DC are CD86+positive.
4 more elements
An in vitro method for generating a population of human tolerogenic dendritic cells (Tr-DC) comprising the steps of:
- a) collecting peripheral blood mononuclear cells (PBMCs) from a subject;
- b) isolating CD14+ cells from collected PBMCs;
- and
- c) exposing said isolated CD14+ cells at the start of culture on day 0 to an effective amount of GM-CSF, IL-4 and IL-10 to generate human Tr-DC,
- wherein the generated human Tr-DC have a marker phenotype comprising:
- CD14+, CD11c+, CD11b+, CD80+, and CD1a−;
- and wherein at least about 92% of the generated human Tr-DC are CD86+.
4 more elements
Dependencies are inferred from the claim text.